Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation.
Topilsky Y, Hasin T, Raichlin E, Boilson BA, Schirger JA, Pereira NL, Edwards BS, Clavell AL, Rodeheffer RJ, Frantz RP, Maltais S, Park SJ, Daly RC, Lerman A, Kushwaha SS.
Topilsky Y, et al. Among authors: edwards bs.
Circulation. 2012 Feb 7;125(5):708-20. doi: 10.1161/CIRCULATIONAHA.111.040360. Epub 2011 Dec 29.
Circulation. 2012.
PMID: 22207715
Clinical Trial.